Citius Pharmaceuticals (CTXR) unit Citius Oncology (CTOR) said Monday it signed a distribution agreement with Cardinal Health (CAH) to support the commercial US rollout of Lymphir, a treatment for adults with relapsed or refractory cutaneous T-cell lymphoma.
Financial terms were not provided.
Cardinal Health will serve as an authorized distributor for the FDA-approved drug, Citius Oncology said.
Price: 1.05, Change: +0.08, Percent Change: +8.25
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.